Apimeds Pharmaceuticals US (APUS) Debt Ratio (2025)

Apimeds Pharmaceuticals US (APUS) reported Debt Ratio of 0.01 for Q4 2025, down 98.98% quarter-over-quarter from 0.96 in Q1 2025.

Apimeds Pharmaceuticals US (APUS) Debt Ratio (2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Debt Ratio for 1 years, with the latest figure at 0.01 in Q4 2025.

  • For the quarter ending Q4 2025, Debt Ratio changed N/A year-over-year to 0.01; the trailing twelve-month figure through Dec 2025 stood at 0.01 (changed N/A YoY), and the FY2025 full-year result was 0.01, changed N/A from the prior year.
  • Debt Ratio for Q4 2025 stood at 0.01, down from 0.96 in the prior quarter.
  • The five-year high for Debt Ratio was 0.96 in Q1 2025, with the low at 0.01 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 0.42
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 0.60
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 0.01
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 0.30
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 0.35
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 0.24
10 Apimeds Pharmaceuticals US 13.93 Mn 10.29 Mn - 0.01

Historic Data

Download Data
DateValue
Dec 31, 2025 0.01
Mar 31, 2025 0.96